Bristol-Myers Squibb Co.’s immuno-oncology treatment Opdivo has now been approved in five tumor types in under two years by the U.S. FDA.
Getting more Americans to enroll for health insurance under President Barack Obama’s healthcare law known as Obamacare is a top priority of his administration until President-elect Donald Trump takes office, the White House said.
The U.S. Drug Enforcement Administration (DEA) said it had temporarily categorized a synthetic opioid nicknamed “pink” as a dangerous drug, after receiving at least 46 reports of deaths associated with its use.
Adult women in Puerto Rico were significantly more likely to develop Zika than men, researchers said, raising new questions about the potential role of sexual transmission of the virus from males to females.
The number of deaths from measles has fallen by 79 percent worldwide since 2000 – due mainly to mass vaccination campaigns – but nearly 400 children still die from the disease every day, global health experts said.
Shares in Swiss-listed drugmaker Cosmo Pharmaceuticals jumped more than 10 percent after it reported its dye tablets helped doctors detect intestinal growths during colonoscopies.
Bristol-Myers Squibb Co. said its blockbuster immunotherapy Opdivo helped patients with advanced stomach cancer live longer in a late-stage study, becoming the first drug of its kind to show a survival benefit in these patients.
In the wake of a failed Phase III clinical trial, Gaithersberg, Md.-based Novavax announced that it plans to cut 30 percent of staff and restructure the company.
Competition is getting tighter in the market to treat non-alcoholic steatohepatitis (NASH). Bristol-Myers Squibb struck a $100 million deal with Osaka, Japan-based Nitto Denko Corp. for rights to that company’s Phase Ib therapy.